144 related articles for article (PubMed ID: 37966921)
21. Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy.
Guan H; Zhou Z; Hou X; Zhang F; Zhao J; Hu K
Asia Pac J Clin Oncol; 2023 Feb; 19(1):35-50. PubMed ID: 35538049
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
[No Abstract] [Full Text] [Related]
23. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
24. Radiotherapy and immune checkpoints inhibitors for advanced melanoma.
Filippi AR; Fava P; Badellino S; Astrua C; Ricardi U; Quaglino P
Radiother Oncol; 2016 Jul; 120(1):1-12. PubMed ID: 27345592
[TBL] [Abstract][Full Text] [Related]
25. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
26. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
27. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
Aboudaram A; Modesto A; Chaltiel L; Gomez-Roca C; Boulinguez S; Sibaud V; Delord JP; Chira C; Delannes M; Moyal E; Meyer N
Melanoma Res; 2017 Oct; 27(5):485-491. PubMed ID: 28858075
[TBL] [Abstract][Full Text] [Related]
28. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis.
Sha CM; Lehrer EJ; Hwang C; Trifiletti DM; Mackley HB; Drabick JJ; Zaorsky NG
Radiother Oncol; 2020 Oct; 151():141-148. PubMed ID: 32717359
[TBL] [Abstract][Full Text] [Related]
29. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review.
Chicas-Sett R; Morales-Orue I; Rodriguez-Abreu D; Lara-Jimenez P
Clin Transl Radiat Oncol; 2018 Feb; 9():5-11. PubMed ID: 29594244
[TBL] [Abstract][Full Text] [Related]
30. Radiotherapy and Immunotherapy in Melanoma Brain Metastases.
Anvari A; Sasanpour P; Kheradmardi MR
Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):1-20. PubMed ID: 36634277
[TBL] [Abstract][Full Text] [Related]
31. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
[TBL] [Abstract][Full Text] [Related]
32. Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases.
Pomeranz Krummel DA; Nasti TH; Izar B; Press RH; Xu M; Lowder L; Kallay L; Rupji M; Rosen H; Su J; Curran W; Olson J; Weinberg B; Schniederjan M; Neill S; Lawson D; Kowalski J; Khan MK; Sengupta S
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):157-163. PubMed ID: 32057994
[TBL] [Abstract][Full Text] [Related]
33. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
[TBL] [Abstract][Full Text] [Related]
34. Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy.
Gabani P; Robinson CG; Ansstas G; Johanns TM; Huang J
Radiother Oncol; 2018 May; 127(2):310-317. PubMed ID: 29534829
[TBL] [Abstract][Full Text] [Related]
35. Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Kropp LM; De Los Santos JF; McKee SB; Conry RM
J Immunother; 2016; 39(9):373-378. PubMed ID: 27662339
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.
Mohamad O; Diaz de Leon A; Schroeder S; Leiker A; Christie A; Zhang-Velten E; Trivedi L; Khan S; Desai NB; Laine A; Albuquerque K; Iyengar P; Arriaga Y; Courtney K; Gerber DE; Hammers H; Choy H; Timmerman R; Brugarolas J; Hannan R
Oncoimmunology; 2018; 7(7):e1440168. PubMed ID: 29900043
[TBL] [Abstract][Full Text] [Related]
37. Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
Haist M; Stege H; Pemler S; Heinz J; Fleischer MI; Graf C; Ruf W; Loquai C; Grabbe S
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680252
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Liu Z; Xu T; Chang P; Fu W; Wei J; Xia C; Wang Q; Li M; Pu X; Huang F; Ge C; Gao Y; Gong S; Liu C; Dong L
Front Pharmacol; 2023; 14():1064227. PubMed ID: 36762107
[No Abstract] [Full Text] [Related]
39. Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer.
Fiorica F; Tebano U; Gabbani M; Perrone M; Missiroli S; Berretta M; Giuliani J; Bonetti A; Remo A; Pigozzi E; Tontini A; Napoli G; Luca N; Grigolato D; Pinton P; Giorgi C
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34068133
[TBL] [Abstract][Full Text] [Related]
40. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
